In a stock market currently obsessed with interest rate cuts and the artificial intelligence (AI) boom, it is easy to overlook the biotechnology sector. However, for investors willing to look beyond the Magnificent Seven, clinical-stage biotech remains one of the few places to find massive, event-driven returns that are largely independent of the broader economy.
MoonLake Immunotherapeutics (NASDAQ: MLTX) is proving this point in real time. The stock rose approximately 10% on the first trading days of February, pushing its price to over $16. This move is part of a broader recovery, with shares up more than 30% over the last month. While volatility is the price of admission in this sector, MoonLake’s recent rally is not based on hype. It is driven by a series of concrete regulatory victories that have fundamentally changed the company’s future.
